Brooke McCormick

Karen van Caulil, PhD, explained why employers evaluating cancer care weigh timely access, quality, and equity alongside cost.

Stephen "Fred" Divers, MD, discusses how COA study data push back on payer bias and support community oncology's long-term sustainability.

David Johnson, MD, MPH, discusses how payer data can reduce low-value cancer care and steer patients to supportive services and cost-efficient sites.

Stephen “Fred” Divers, MD, discusses findings showing community oncology delivers outcomes comparable with academic care for breast cancer and NSCLC.

Stephen "Fred" Divers, MD, previews PCOC 2026, including his session on the Oncology Care Index and the gap in AI adoption in oncology.

Christine Pfaff, RPh, MBA, discusses barriers to community cellular therapy delivery and the need for new business models and payer collaboration.

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.

Jeff Hunnicutt emphasized vetting prior authorization vendors, scaling beyond single use cases, and AI's potential to streamline workflows.

Rosa Novo discusses tailoring cancer benefits to workforce needs, improving access and prevention, and return-to-work support.

Employers can advance patient-centered oncology care through proactive benefits, quality data, navigation, and tailored support, Amanda Green, MPH, said.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Lalan Wilfong, MD, discusses how model assumptions, cohort design, and risk adjustment shape performance and accountability in value-based oncology.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

AI tools can ease administrative burden in community oncology, but practices face adoption, security, compliance, bias, and error concerns.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

A higher weight-adjusted waist index (WWI) was independently linked to greater all-cause and CVD mortality in CKD, partly via inflammation.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

The final part explores individualized CAR T and bispecific therapy selection in multiple myeloma and the need for stronger academic-community collaboration.

August authors Jeff Romine, PhD, and Kofi Essel, MD, MPH, found grocery assistance linked to fewer diabetes complications and better medication adherence.

In part 2, Christos Vaklavas, MD, discusses clinical trial complexity and the shift toward more accessible treatment delivery.

Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.

Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.